scholarly journals Continuous Infusion Cisplatin and Etoposide Chemotherapy for Cancer of Unknown Primary Site (CUPS) in Taiwan, a Region with a High Prevalence of Endemic Viral Infections

1998 ◽  
Vol 28 (7) ◽  
pp. 431-435 ◽  
Author(s):  
J. M. Liu ◽  
Y. M. Chen ◽  
Y. Chao ◽  
S. M. Liu ◽  
C. M. Tiu ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Viral Infections ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
High Prevalence

scholarly journals Dermatomyositis Associated with Cancer of Unknown Primary Site

2007 ◽  
Vol 22 (Suppl) ◽  
pp. S174 ◽  
Author(s):  
Hyung Il Kim ◽  
Sung Hoon Chung ◽  
Jun Eul Hwang ◽  
Sang Ho Kim ◽  
Jae Sook Ahn ◽  
...  
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site

scholarly journals Cancer of Unknown Primary Site Mimicking Retroperitoneal Fibrosis

2018 ◽  
Vol 93 (6) ◽  
pp. 575-581
Author(s):  
Chan Keol Park ◽  
Su-Jin Yoo ◽  
In Seol Yoo ◽  
Jinhyun Kim ◽  
Seung Cheol Shim ◽  
...  
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site

scholarly journals Resection Of A Retroperitoneal Cancer Of Unknown Primary Site After Chemoradiation Therapy: A Case Report

2020 ◽  
Author(s):  
Tomonari Suetsugu ◽  
Nobuhisa Matsuhashi ◽  
Hiroshi Tsuchiya ◽  
Takao Takahashi ◽  
Masahiro Fukada ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Iliac Artery ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Multidisciplinary Therapy ◽  
Carcinoma Of Unknown Primary

Abstract Background: Complete recovery from retroperitoneal squamous cell carcinoma of unknown primary site treated by multidisciplinary therapy is extremely rare.Case presentation: A 78-year-old man was referred to our hospital due to a mass measuring 8 cm in size in the left pelvic retroperitoneal area, which was diagnosed as a cancer of unknown primary site. The pathological type was squamous cell carcinoma. The left iliac artery/vein and ureter were involved in the tumor, and the tumor caused severe left leg pain. Although inflammation and symptoms were severe, palliative radiotherapy was considered. After that, biweekly combined therapy with docetaxel, cisplatin, and fluorouracil was planned. After 5 courses of chemotherapy, the tumor diameter reduced from 11.6 cm to 4 cm in size. In addition, the border between the iliac vessels, urinary tract and tumor became apparent. The patient underwent radical resection of the tumor 8 months after the treatment started. The left ureter and the external/internal iliac artery were preserved, but the external iliac vein was sacrificed because of the possibility of tumor invasion. The postoperative course was free of complications, and the patient was discharged 10 days after the operation. The histopathological findings showed no residual viable tumor cells or foreign body-type giant cells with necrosis. The pathological effect of chemotherapy was defined as Grade 3 (pathological complete response). The patient has experienced no recurrence or distant metastasis for 4 years.Conclusions: Multidisciplinary therapy succeeded in treating a retroperitoneal squamous cell carcinoma of unknown primary site with preservation of organ function.

Cancer of Unknown Primary Site

Oncology ◽  
2007 ◽  
pp. 1119-1132 ◽  
Author(s):  
F. Anthony Greco ◽  
John D. Hainsworth
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site

Cancer of unknown primary site

2016 ◽  
pp. 965-974
Author(s):  
Nicholas Pavlidis ◽  
George Pentheroudakis
Keyword(s):  
Expression Profiling ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Clinical Intuition ◽  
Genome Wide ◽  
Genetic Signatures ◽  
Genome Wide Expression ◽  
Tumour Origin

This chapter covers cancer of unknown primary site (CUP), and includes information on epidemiology, molecular biology, pathology, and multidisciplinary management of clinicopathological subsets. Previously, these tumours were diagnosed and treated based on clinical presentation, light microscopy and clinical intuition. Today, the majority of cancers of unknown primary site are becoming less unknown, more accurately classified, and appropriately treated by the use of multiplex or genome-wide expression profiling platforms. These techniques allow for precise and correct knowledge of the true tumour origin, leading to more rational and effective treatment. However, there also may be genetic signatures that are primary-independent, pro-metastatic, and possibly CUP-specific.

scholarly journals Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?

2020 ◽  
Vol 11 (13) ◽  
pp. 3919-3931 ◽  
Author(s):  
Alaa T. Alshareeda ◽  
Batla S. Al-Sowayan ◽  
Reem R. Alkharji ◽  
Sahar M. Aldosari ◽  
Abdullah M. Al subayyil ◽  
...  
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Real Entity

scholarly journals Malignant pleural effusion and cancer of unknown primary site: a review of literature

2019 ◽  
Vol 7 (15) ◽  
pp. 353-353 ◽  
Author(s):  
Saed Fathi Awadallah ◽  
Mark R. Bowling ◽  
Nitika Sharma ◽  
Arjun Mohan
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Review Of Literature ◽  
Unknown Primary Site

scholarly journals Organizing pneumonia secondary to lung cancer of unknown primary site

2019 ◽  
Vol 28 ◽  
pp. 100892 ◽  
Author(s):  
Ruolin Mao ◽  
Lianpeng Zhang ◽  
Jun Hou ◽  
Yining Zou ◽  
Lei Zhu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Organizing Pneumonia ◽  
Unknown Primary Site

Cancer of Unknown Primary Site: Missing Primary or Missing Biology?

2007 ◽  
Vol 12 (4) ◽  
pp. 418-425 ◽  
Author(s):  
George Pentheroudakis ◽  
Evangelos Briasoulis ◽  
Nicholas Pavlidis
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site
Sign in / Sign up

Export Citation Format

Share Document